Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Blood (2019) 134 (Supplement_1): 4306.

https://doi.org/10.1182/blood-2019-123824

Published: 2019

Journal Articles

Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance)

Lawrence D Kaplan, MD, Matthew J. Maurer, MS, Wendy Stock, MD, Nancy L. Bartlett, MD, Noreen Fulton, BS, Adam Pettinger, John C. Byrd, MD, Kristie A. Blum, MD, Ann S. LaCasce, MD MSc, David Duane Hurd, MD, Amy S. Ruppert, MAS, PhD, Francisco J. Hernandez-Ilizaliturri, MD, John P. Leonard, MD, Bruce Cheson, MD

Blood (2018) 132 (Supplement 1): 146.

https://doi.org/10.1182/blood-2018-99-112655

Published: 2018

Journal Articles

Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration

Matthew J Maurer, MS, Amy S. Ruppert, MAS, PhD, Brian K. Link, MD, Lawrence D Kaplan, MD, David J Inwards, MD, Andrew L. Feldman, MD, Eric D. Hsi, MD, Adam Pettinger, Jonathon B. Cohen, MD MS, Peter Martin, FRCPC, MD MS, Brad S Kahl, MD, Nancy L. Bartlett, MD, James R. Cerhan, MD PhD, John P. Leonard, MD, Thomas M. Habermann, MD

Blood (2018) 132 (Supplement 1): 2878.

https://doi.org/10.1182/blood-2018-99-110558

Published: 2018

Journal Articles

Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

Ayalew Tefferi, MD, Betsy R. LaPlant, MS, Kebede Begna, MD, Mrinal M. Patnaik, MBBS, Terra L Lasho, PhD, Darci Zblewski, CNP, Christy Finke, BS, Lauren Schimek, Adam Pettinger, Curtis A. Hanson, MD, Naseema Gangat, MD, Animesh Pardanani, MBBS, PhD

Blood (2014) 124 (21): 634.

https://doi.org/10.1182/blood.V124.21.634.634

Published: 2014

Journal Articles

Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)

Tait D. Shanafelt, MD, Betsy R. LaPlant, MS, Timothy G Call, MD, Daniel Nikcevich, MD PhD, Jose F. Leis, MD PhD, Wei Ding, MD PhD, Adam Pettinger, Daniel L. Van Dyke, PhD, Diane F. Jelinek, Curtis A. Hanson, MD, Neil E. Kay, MD

Blood (2014) 124 (21): 4673.

https://doi.org/10.1182/blood.V124.21.4673.4673

Published: 2014

Journal Articles

Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)

Tait D. Shanafelt, Alan G. Ramsay, Clive S. Zent, Jose F. Leis, Han W. Tun, Timothy G. Call, Betsy LaPlant, Deborah Bowen, Adam Pettinger, Diane F. Jelinek, Curtis A. Hanson, Neil E. Kay

Blood (2013) 121 (20): 4137–4141.

https://doi.org/10.1182/blood-2012-12-470005

Published: 2013

Includes: Supplemental data

NARROW

A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance)

Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration

Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)

Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance)

Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration

Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)

Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only